E-LIB Suche - Ergebnisse für: Dave, K

1

P160 Evaluating the process of initiating elexacaftor/tezac..:

Thomas, L.H. ; Lau, D. ; Dave, K.
Journal of Cystic Fibrosis. 23 (2024) - p. S104 , 2024

Link: https://doi.org/10.1016/..

2

EPS8.06 "'Snot a problem": physiotherapy outcomes from init..:

McDowell, R. ; Carter, H. ; Addy, C...
Journal of Cystic Fibrosis. 23 (2024) - p. S58 , 2024

Link: https://doi.org/10.1016/..

3

P833 Burden of steroid use in patients with moderate ulcera..:

Shah, S ; Knight, H ; O'Neill, G...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1551-i1553 , 2024

Link: https://doi.org/10.1093/..

4

EPH29 The Cost of Managing Safety Events: Ozanimod Versus T..:

Paris, J ; Stephens, S ; Oddershede, L.
Value in Health. 25 (2022) 12 - p. S196 , 2022

Link: https://doi.org/10.1016/..

5

HSD12 Reasons for Choice and Areas for Improvements of Adva..:

Najlerahim, S ; Kershaw, J ; O'Neill, G...
Value in Health. 25 (2022) 12 - p. S275 , 2022

Link: https://doi.org/10.1016/..

6

P076 Using the Cystic Fibrosis Foundation consensus guideli..:

Dave, K. ; Dunk, R. ; Madge, S...
Journal of Cystic Fibrosis. 20 (2021) - p. S62 , 2021

Link: https://doi.org/10.1016/..

7

P077 Clinical factors affecting timing of referral for lung..:

Dave, K. ; Reed, A. ; Baker, L....
Journal of Cystic Fibrosis. 20 (2021) - p. S62-S63 , 2021

Link: https://doi.org/10.1016/..

8

P075 Are there lessons to be learned from cystic fibrosis p..:

Dave, K. ; Dunk, R. ; Madge, S...
Journal of Cystic Fibrosis. 20 (2021) - p. S61-S62 , 2021

Link: https://doi.org/10.1016/..

9

PCN245 Opposing Duration of Treatment Effect Assumptions US..:

Davé, K. ; Strunz-McKendry, T. ; Felizzi, F...
Value in Health. 23 (2020) - p. S466 , 2020

Link: https://doi.org/10.1016/..

10

P057 Assessing the timing and clinical characteristics of p..:

Dave, K. ; Dunk, R. ; Madge, S...
Journal of Cystic Fibrosis. 19 (2020) - p. S71 , 2020

Link: https://doi.org/10.1016/..

11

PCN236 A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFEC..:

Smare, C. ; Dave, K. ; Juarez-Garcia, A....
Value in Health. 22 (2019) - p. S481 , 2019

Link: https://doi.org/10.1016/..

12

Specificity of extended O-aryloxycarbonyl hydroxamates as i..:

Malico, Alexandra A. ; Dave, K. ; Adediran, S.A..
Bioorganic & Medicinal Chemistry. 27 (2019) 7 - p. 1430-1436 , 2019

Link: https://doi.org/10.1016/..

13

PCN227 A PARTITIONED SURVIVAL MODEL TO DETERMINE COST-EFFEC..:

Smare, C. ; Dave, K. ; Juarez-Garcia, A....
Value in Health. 22 (2019) - p. S480 , 2019

Link: https://doi.org/10.1016/..

14

PRM56 - COULD ERG PREFERENCES FOR DIFFERENT OVERALL SURVIVA..:

Berardi, A ; Dave, K ; Macaulay, R.
Value in Health. 21 (2018) - p. S364 , 2018

Link: https://doi.org/10.1016/..

15

Feasibility and Safety of Multicenter Tissue and Biofluid S..:

Chahine, Lana M. ; Beach, Thomas G. ; Seedorff, Nicholas...
Journal of Parkinson's Disease. 8 (2018) 4 - p. 517-527 , 2018

Link: https://doi.org/10.3233/..